10-Q: ALT5 Sigma Q2 Loss Deepens, Plans $750M Capital Raise

ALT5 Sigma Corporation reported a significant net loss for Q2 2025 despite revenue growth from recent fintech acquisitions, while announcing a substantial $750 million capital raise and ATM offering.

Summary

• ALT5 Sigma Corporation, formerly JanOne Inc., changed its corporate name and Nasdaq ticker from JAN to ALTS effective July 15, 2024.
• The company operates in Fintech, Biotechnology (now discontinued operations), and Corporate and Other segments.
• Revenue for the 13 weeks ended June 28, 2025, increased to $6.378 million from $2.169 million in the prior year period, primarily due to the acquisitions of ALT5 Subsidiary (May 2024) and Mswipe (May 2025).
• Gross profit for the 13 weeks ended June 28, 2025, increased to $2.775 million from $1.098 million.
• Net loss for the 13 weeks ended June 28, 2025, significantly widened to $9.115 million, compared to a net income of $0.589 million in the prior year period.
• Net loss for the 26 weeks ended June 28, 2025, was $11.976 million, compared to a net loss of $1.555 million in the prior year period.
• Basic and diluted net loss per share for the 13 weeks was $0.49, compared to net income per share of $0.07 in the prior year.
• Basic and diluted net loss per share for the 26 weeks was $0.70, compared to a net loss per share of $0.18 in the prior year.
• Adjusted EBITDA for the 13 weeks ended June 28, 2025, was a loss of $1.291 million, compared to a loss of $0.917 million in the prior year period.
• Adjusted EBITDA for the 26 weeks ended June 28, 2025, was a loss of $2.331 million, compared to a loss of $1.740 million in the prior year period.
• The Biotechnology segment (Alyea Therapeutics Corporation) has been presented as discontinued operations following the company's formal separation disclosure on May 21, 2025.
• Cash on hand increased to $9.560 million as of June 28, 2025, from $7.177 million as of December 28, 2024.
• Total assets increased to $94.686 million as of June 28, 2025, from $82.436 million as of December 28, 2024.
• Total liabilities increased to $61.579 million as of June 28, 2025, from $53.769 million as of December 28, 2024.
• The company disclosed material weaknesses in internal control over financial reporting, including insufficient written documentation of policies and procedures, and insufficient resources for segregation of duties.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant and worsening net losses, negative Adjusted EBITDA, and disclosed material weaknesses in internal controls. While there are strategic acquisitions and a large capital raise planned, the underlying financial performance and going concern risk are substantial concerns. The capital raise, while necessary, also implies significant dilution and a pressing need for funds.

Positives

• Revenue significantly increased by $4.2 million for the 13 weeks and $9.7 million for the 26 weeks ended June 28, 2025, driven by recent fintech acquisitions.
• Gross profit increased by $1.7 million for the 13 weeks and $4.3 million for the 26 weeks ended June 28, 2025.
• Strategic acquisitions of ALT5 Subsidiary, Qoden Cryptocurrency Exchange Software, and Mswipe have expanded the company's fintech capabilities.
• Cash and cash equivalents increased to $9.560 million as of June 28, 2025, from $7.177 million at the end of 2024.
• The company plans a significant capital raise of $750 million through a Registered Direct Offering and a concurrent Private Placement, along with a $1 billion At-The-Market (ATM) agreement, to fund operations, settle debt, and invest in cryptocurrency treasury.

Negatives

• Net loss from continuing operations significantly widened to $5.502 million for the 13 weeks ended June 28, 2025, from a net income of $0.970 million in the prior year period.
• Total net loss for the 13 weeks ended June 28, 2025, was $9.115 million, a substantial deterioration from a net income of $0.589 million in the prior year.
• Total net loss for the 26 weeks ended June 28, 2025, was $11.976 million, significantly higher than the $1.555 million loss in the prior year period.
• Operating loss increased for the 26 weeks ended June 28, 2025, to $3.725 million from $3.584 million in the prior year.
• Adjusted EBITDA remained negative and worsened for both the 13-week and 26-week periods.
• The company identified material weaknesses in its internal control over financial reporting, indicating a lack of effective controls.
• The company's ability to continue as a going concern is dependent on future capital raises or structured arrangements.
• Significant increase in interest expense, net, by approximately $560,000 for the 13 weeks and $1.0 million for the 26 weeks ended June 28, 2025.

Risks

• The company's ability to continue as a going concern is dependent on securing future capital raises or structured arrangements.
• Ongoing litigation, including a class action lawsuit (Sieggreen), a lease guarantee dispute (Main/270), a loan guarantee dispute (Gulf Coast Bank and Trust), and a services fee dispute (First Capital Consulting, Inc.), could result in significant financial liabilities.
• The company faces risks related to its material weaknesses in internal control over financial reporting, which could affect financial reporting reliability.
• The substantial capital raise involves significant potential dilution for existing shareholders.
• The success of the Fintech segment is subject to the volatility of digital asset markets and regulatory changes.
• There is no assurance that the Biotechnology segment's product (JAN123) will receive FDA approval or result in material sales, despite Orphan Drug Designation.

Future Outlook

The company intends to raise significant funds through a Registered Direct Offering and a concurrent Private Placement, totaling $750 million in gross proceeds and $750 million in WLFI tokens, respectively. These funds are earmarked for settling existing litigation, paying down debt, funding current business operations, and establishing a cryptocurrency treasury. Additionally, the company plans to utilize an At-The-Market (ATM) agreement to sell up to $1 billion in common stock. The company's ability to continue as a going concern is dependent on the success of these future capital raises or structured arrangements, which are also intended to fund required testing for FDA approval of JAN123 and other strategic investments.

Management Comments

• Management believes that Adjusted EBITDA is an important indicator of the operational strength and performance of the business, including the business's ability to fund acquisitions and other capital expenditures, and to service its debt.
• Management cannot make any assurances that such financing will be secured to fund the required testing to obtain FDA approval of JAN123, as well as to fund day-to-day operations.

Industry Context

The company's strategic acquisitions in the fintech sector, particularly ALT5 Sigma, Qoden, and Mswipe, align with the broader industry trend of increasing adoption of blockchain-powered technologies, digital assets, and integrated payment solutions. These moves position ALT5 Sigma to bridge traditional finance with the growing crypto economy. The spin-off of the Biotechnology segment (Alyea) allows the company to streamline its focus on the fintech sector, while the biotech entity can pursue its specialized pain management drug development independently, potentially attracting dedicated investment in the pharmaceutical space.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards.

Corporate Governance

Legal Proceedings

• SEC Complaint: Settled on May 28, 2024, with the company agreeing to pay a civil penalty of $250,000 in four quarterly payments of $62,500. Remaining allegations are against the Chief Financial Officer, Virland Johnson.
• Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants: Company added as a defendant on March 6, 2023, for alleged violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. A Motion to Dismiss was granted with leave to amend, and a Second Amended Complaint was filed on October 31, 2024. The company filed another Motion to Dismiss on December 16, 2024, awaiting a ruling.
• Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant: Company is a defendant as a guarantor of a lease. Plaintiff seeks approximately $90,000 from the company and approximately $1,420,000 jointly with ApplianceSmart. Trial has been conducted, and the company is awaiting the judge's decision.
• Gulf Coast Bank and Trust vs. ALT5 Sigma Corporation, et al.: Plaintiff seeks approximately $1.6 million related to a loan guarantee for a prior subsidiary, ARCA Recycling Inc. The company posted a $900,000 cash bond. Experts were designated by July 31, 2025, and depositions are being scheduled for August, with trial expected in 2026.
• First Capital Consulting, Inc. DBA Trusaic vs. ALT5 Sigma Corporation: Plaintiff seeks $97,696.42 plus costs and interest for unpaid obligations of former subsidiaries (ARCA Recycling Inc. and Customer Connexx LLC). Trial is scheduled for June 29, 2026.

Related Party Transactions

• Tony Isaac, the company's President, is the father of Jon Isaac, President and CEO of Live Ventures Incorporated, and a managing member of Isaac Capital Group LLC (ICG). Tony Isaac is also a board member of Live Ventures.
• The company shares certain executive, accounting, and legal services with Live Ventures, totaling approximately $30,000 for the 13 weeks and $58,000 for the 26 weeks ended June 28, 2025.
• ALT5 rents approximately 9,900 square feet of office space from Live Ventures in Las Vegas, Nevada.
• Promissory notes with Live Ventures and ICG, initially $300,000 each, were amended on February 7, 2024, to include a convertibility provision at $0.61 per share. As of June 28, 2025, balances outstanding were approximately $0.3 million for Live Ventures and $30,000 for ICG.
• Short-term demand advances from ICG (approximately $23,000 outstanding as of June 28, 2025) and Novalk Apps SAA, LLP (approximately $0.1 million outstanding as of June 28, 2025). Juan Yunis, an employee of Live Ventures, is the managing member of Novalk.

Stakeholder Impact

• Shareholders face significant potential dilution from the planned Registered Direct Offering, Private Placement, and ATM offering, which could substantially increase the number of outstanding shares.
• Shareholders are also impacted by the company's widening net losses and the disclosed material weaknesses in internal controls, which raise concerns about financial performance and reporting reliability.
• Creditors holding existing debt may see their obligations settled or converted to equity as part of the planned capital raise, potentially altering their risk exposure.
• Employees in the Fintech segment may experience stability or growth due to recent acquisitions and strategic focus, while those in the Biotechnology segment (Alyea) are part of a spun-off entity, leading to a decoupled operational structure.
• Customers of the Fintech platforms (ALT5 Pay, ALT5 Prime, Mswipe, Qoden) may benefit from expanded services and enhanced capabilities due to the acquisitions and planned investments in cryptocurrency treasury operations.
• The company's ability to fund its operations and strategic initiatives, including the Phase IIb clinical trials for JAN123, is critical for all stakeholders, and its dependence on future capital raises introduces uncertainty.

Next Steps

• Hold an annual or special meeting of stockholders on or prior to September 30, 2025, to obtain shareholder approval for the Exchange Cap and the amendment to the Articles of Incorporation related to the Private Placement.
• If shareholder approval is not obtained at the first meeting, call a meeting every ninety days thereafter until approval is secured.
• File a registration statement for the resale of PIPE Securities within 15 days of the Private Placement closing and maintain its effectiveness.
• Schedule depositions for experts in the Gulf Coast Bank and Trust litigation, with trial expected in 2026.
• Await the judge's decision in the Main/270, LLC litigation.
• Proceed with trial in the First Capital Consulting, Inc. DBA Trusaic litigation, scheduled for June 29, 2026.

Key Dates

Recommendation

The company reported a substantial increase in net losses for both the quarter and year-to-date periods, indicating a significant deterioration in financial performance despite revenue growth from acquisitions. The disclosure of material weaknesses in internal controls over financial reporting raises serious concerns about the reliability of financial statements and overall corporate governance. Furthermore, the company explicitly states a going concern dependency on future capital raises, which, while large, also imply significant dilution for existing shareholders and a pressing need for funds. The ongoing legal proceedings add further financial uncertainty. Given the severe financial distress, control deficiencies, and high dilution risk, the stock presents a high-risk profile.

Keywords

Fintech, Cryptocurrency, Blockchain, Digital Assets, Payments, Biotechnology, SEC Filing, 10-Q, Capital Raise, Nasdaq, Mswipe, Qoden, Alyea Therapeutics